Trials Assessing Parmacotherapeutic Management of Aggression in Psychiatric Patients: Comparability with Clinical Practice

Abstract

Introduction: In a previous review of randomized controlled trials (RCTs) on the pharmacotherapeutic management of aggression, it was shown that there is only weak evidence of effectiveness. In the present study we aim to determine comparability of patients included in these RCTs and patients of psychiatric long-stay wards.

Methods: Exclusion criteria that were used in at least 20% of the RCTs were applied to a sample of aggressive inpatients from clinical practice, in order to find what proportion of these patients would be eligible to participate in the reviewed, high quality RCTs.

Results: Only 30% of aggressive psychiatric patients as seen in clinical practice would be eligible to participate in a typical randomized controlled trial based on the most frequently applied exclusion criteria.

Discussion: The low comparability of patients included in RCTs with those seen in clinical practice may decrease the generalizability of the findings form RCTs to clinical practice.

References

• 1 Allan ER, Alpert M, Sison CE. et al . Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.  J Clin Psychiatry. 1996;  57 455-459
• 2 Alpert M, Allan ER, Citrome L. et al . A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients.  Psychopharmacol Bull. 1990;  26 367-371
• 3 Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.  J Clin Psychopharmacol. 1996;  16 38-44
• 4 Caldwell A. Hospital accountability: perceptions and costs.  Front Health Serv Manage. 1992;  8 38-40
• 5 Caspi N, Modai I, Barak P. et al . Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study.  Int Clin Psychopharmacol. 2001;  16 111-115
• 6 Citrome L, Casey DE, Daniel DG. et al . Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.  Psychiatr Serv. 2004;  55 290-294
• 7 Citrome L, Volavka J, Czobor P. et al . Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.  Psychiatr Serv. 2001;  52 1510-1514
• 8 Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.  Arch Gen Psychiatry. 1997;  54 1081-1088
• 9 Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia.  J Clin Psychopharmacol. 1995;  15 243-249
• 10 Davidson JR, McLeod MN, Turnbull CD. et al . A comparison of phenelzine and imipramine in depressed inpatients.  J Clin Psychiatry. 1981;  42 395-397
• 11 Davidson JR, Landerman LR, Farfel GM. et al . Characterizing the effects of sertraline in post-traumatic stress disorder.  Psychol Med. 2002;  32 661-670
• 12 de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder.  Eur Neuropsychopharmacol. 1994;  4 479-486
• 13 Dorrego MF, Canevaro L, Kuzis G. et al . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings.  J Neuropsychiatry Clin Neurosci. 2002;  14 289-295
• 14 Edlund MJ, Craig TJ, Richardson MA. Informed consent as a form of volunteer bias.  Am J Psychiatry. 1985;  142 624-627
• 15 Fassino S, Leombruni P, Daga G. et al . Efficacy of citalopram in anorexia nervosa: a pilot study.  Eur Neuropsychopharmacol. 2002;  12 453-459
• 16 Fava M, Nierenberg AA, Quitkin FM. et al . A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia.  Psychopharmacol Bull. 1997;  33 101-103
• 17 Frankenburg F, Zanarini M. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.  J Clin Psychiatry. 2002;  63 442-446
• 18 Goedhard LE, Stolker JJ, Heerdink ER. et al . Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review.  J Clin Psychiatry. 2006;  67 1013-1024
• 19 Hollander E, Allen A, Lopez RP. et al . A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.  J Clin Psychiatry. 2001;  62 199-203
• 20 Hollander E, Tracy KA, Swann AC. et al . Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders.  Neuropsychopharmacology. 2003;  28 1186-1197
• 21 Hunter M, Carmel H. The cost of staff injuries from inpatient violence.  Hospital and Community Psychiatry. 1992;  43 586-588
• 22 Jadad AR, Moore RA, Carroll D. et al . Assessing the quality of reports of randomized clinical trials: is blinding necessary?.  Control Clin Trials. 1996;  17 1-12
• 23 Lipman RS, Covi L, Rickels K. et al . Imipramine and chlordiazepoxide in depressive and anxiety disorders. I. Efficacy in depressed outpatients.  Arch Gen Psychiatry. 1986;  43 68-77
• 24 Maoz G, Stein D, Meged S. et al . The antiaggressive action of combined haloperidol-propranolol treatment in schizophrenia.  European Psychologist. 2000;  5 312-325
• 25 Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.  J Clin Psychiatry. 1997;  58 538-546
• 26 Mattes JA. Comparative effectiveness of carbamazepine and propranolol for rage outbursts.  J Neuropsychiatry Clin Neurosci. 1990;  2 159-164
• 27 McDougle CJ, Naylor ST, Cohen DJ. et al . A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.  Arch Gen Psychiatry. 1996;  53 1001-1008
• 28 Min SK, Rhee CS, Kim CE. et al . Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.  Yonsei Med J. 1993;  34 179-190
• 29 Monnelly EP, Ciraulo DA, Knapp C. et al . Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder.  J Clin Psychopharmacol. 2003;  23 193-196
• 30 Nickel MK, Nickel C, Mitterlehner FO. et al . Treatment of aggression with topiramate in male borerline patients: a double-blind, placebo-controlled study.  Biol Psychiatry. 2005;  57 495-499
• 31 Nijman H, Muris P. et al . The staff observation aggression scale Revised (SOAS-R).  Aggress Behav. 1999;  25 197-209
• 32 Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.  Br J Psychiatry. 1995;  166 712-726 ; discussion 727-733
• 33 Ratey JJ, Sorgi P, O'Driscoll GA. et al . Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.  J Clin Psychiatry. 1992;  53 41-46
• 34 Rinne T, van den Brink W, Wouters L. et al . SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.  Am J Psychiatry. 2002;  159 2048-2054
• 35 Salzman C, Wolfson AN, Schatzberg A. et al . Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.  J Clin Psychopharmacol. 1995;  15 23-29
• 36 Soloff PH, George A, Nathan S. et al . Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.  J Clin Psychopharmacol. 1989;  9 238-246
• 37 Soloff PH, George A, Nathan RS. et al . Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.  Arch Gen Psychiatry. 1986;  43 691-697
• 38 Starfield B. Quality-of-care research: internal elegance and external relevance.  JAMA. 1998;  280 1006-1008
• 39 Tlusta E, Handoko KB, Majoie M. et al . Clinical relevance of patients with epilepsy included in clinical trials.  Epilepsia. 2008;  49 1479-1480
• 40 van der Kolk BA, Dreyfuss D, Michaels M. et al . Fluoxetine in posttraumatic stress disorder.  J Clin Psychiatry. 1994;  55 517-522
• 41 Vartiainen H, Tiihonen J, Putkonen A. et al . Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia.  Acta Psychiatr Scand. 1995;  91 348-351
• 42 Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.  J Clin Psychiatry. 2001;  62 849-854
• 43 Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.  J Clin Psychiatry. 2004;  65 903-907
• 44 Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?.  Am J Psychiatry. 2002;  159 469-473
• 45 Wisniewski SR, Rush AJ, Nierenberg AA. et al . Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D Report.  Am J Psychiatry. 2009;  166 599-607

Correspondence